Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide orodispersible tablets for prevention of esophageal stricture after endoscopic submucosal dissection
NL-OMON60270Phase 2Completed
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- May 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of budesonide in Esophageal stricture (3 arms), sponsored by Dr. Falk Pharma GmbH. Primary endpoint: Percentage of patients free of strictures at week 8. Started May 2020; status: completed.
02
Drugs
budesonide
03
Conditions
Esophageal stricture
Beyond the preview
Go deeper on NL-OMON60270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60270.